White Paper | Dr.Reddys API

Dr. Reddy's Mirabegron API offering in both alpha and amorphous form

Read through our technical sheet on Mirabegron API to get a glimpse of our multi-step scalable synthetic approach with effective analytical characterization resulting in a highly pure API.

Dr. Reddy's…

Palbociclib – how a novel process development approach provides IP advantages

This whitepaper outlines how Dr. Reddy's holistic development approach can help our API partners across geographies to provide patients early access to the generic alternative of Palbocicilb while gaining or maintaining competitive advantage…

Dr. Reddy's Elagolix API offering leverages a well rounded Quality by Design approach

The technical product sheet on our Elagolix API describes the Quality by Design (QbD) approach taken by Dr. Reddy's R&D team to develop the product. As a result, Dr. Reddy's is one of the first and few generic API manufacturer in the world to…

Gliflozins – an attractive opportunity for early market access

This whitepaper outlines the Dr. Reddy's Gliflozins API portfolio that has been developed through the integrated understanding of IP, regulatory affairs, process development (API & formulation), and API manufacturing in order to ensure early e…

Sacubitril/Valsartan (LCZ696) – Bringing yet another advantage through innovative API offerings

Our team of process and analytical experts draw on their integrated understanding in both the development and manufacturing of the API and the formulation. This is of particular importance when it comes to the characterization of a molecular compl…

Dr. Reddy’s Flow Chemistry experts share their perspectives in panel discussion of Chemistry Today

June 2020

Dr. Reddy’s Flow Chemistry experts, Srividya Ramakrishnan and Rakeshwar Bandichhor, recently participated in the panel discussion of Chemistry Today, where they shared their perspectives on flow technology and its potential to be…

A closer look on how Dr. Reddy's met the stringent regulatory requirement of genotoxic impurities in Ranolazine

Genotoxic impurities (GTIs) have recently challenged the pharmaceutical industry by virtue of their presence at a level of parts per million (ppm) in drug products, especially in high dosage molecules like Ranolazine, which has a prescribed maximu…

Famotidine and Nizatidine APIs: NDMA controlled, customized particle distribution, supply chain security

For more than two decades, Dr. Reddy's has been recognized as one of the largest manufacturers of H2 receptor antagonist APIs such as Famotidine and Nizatidine. Our Tidine APIs are used by formulation companies across Europe, US, Japan, Middle-Eas…

Sitagliptin case: Enhancing formulation development and early market access through an integrated understanding of key API attributes

Our team of experts draw on their integrated understanding in the development and manufacturing of the Sitagliptin API and the formulation. This is of particular importance when it comes to particle engineering and powder flow characteristics whic…

Sugammadex Sodium – The impact of an integrated understanding from API to formulation on injectable formulation success

Sugammadex Sodium is one of the key molecules in Dr. Reddy’s API portfolio and an ideal use case on how a thorough understanding of the interaction between API and formulation can lead to a successful formulation development. Read our latest white…

Meeting the New Regulatory Requirements in Sartan API Production

Manufacturer of APIs are now required to review their manufacturing processes and prove the absence of nitrosamine impurities. This whitepaper outlines the regulations and a case study on how Dr. Reddy’s Sartan API’s (such as Valsartan) already ad…